China has slashed the price of dozens of top drugs from multinationals such as Roche, GlaxoSmithKline and AstraZeneca by as much as 70 per cent as a condition of adding them to a government health insurance scheme.
中國(guó)促使羅氏(Roche)、葛蘭素史克(GSK)和阿斯利康(AstraZeneca)等跨國(guó)公司將數(shù)十種重點(diǎn)藥品降價(jià)，其中降幅最高的達(dá)到70%，以此為條件將這些藥品納入政府醫(yī)保藥品目錄。
您已閱讀11%（306字），剩余89%（2536字）包含更多重要信息，訂閱以繼續(xù)探索完整內(nèi)容，并享受更多專屬服務(wù)。